Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aflibercept biosimilar - Momenta Pharmaceuticals/Viatris

Next Previous
Drug Profile

Aflibercept biosimilar - Momenta Pharmaceuticals/Viatris

Alternative Names: Aflibercept biosimilar - Momenta Pharmaceuticals; aflibercept-jbvf; M-710; MYL-1701P; Yesafili

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocon; Momenta Pharmaceuticals
  • Developer Biocon; Momenta Pharmaceuticals; Viatris Inc
  • Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Choroidal neovascularisation; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration

Most Recent Events

  • 15 Apr 2025 Regenron Pharmaceuticals in-licenses aflibercept bosimilar for commercial launch from Biocon Biologics
  • 15 Apr 2025 United States Court of Appeals for the Federal Circuit dismisses pending patent appeal filed by Regeneron Pharmaceuticals and Biocon Biologics
  • 15 Apr 2025 Biocon Biologics and Regeneron pharmaceuticals plans to launch Aflibercept biosimilar in USA in second half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top